Pricing Log in Create free account
Friday 6 November 2026 Export PRCT’s income statement to Excel — free account

PROCEPT BioRobotics Corporation

PRCT Healthcare Medical Devices

PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.

Revenue
+18.0%
EPS
−21.1%
Free cash flow
−1.57%
Total debt
+0.39%

Quarter to September 2026, against a year earlier

20.35 0.08 +0.39%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−11.6×
Dividend yield
—
F-score
5/9
Altman Z
6.44
Beneish M
−2.86
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 10.98
Sold, $m 0.62
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — 1 — — —
Sell — — — 6 — — 3 — — 3 — —
Insider Ownership 4.72%

Capital & Financial Ratios $m

Size
Market Cap 1,160.00
Revenue ttm 352.30
Net income ttm (114.86)
Free cash flow ttm (85.07)
Net debt Q (166.60)
Valuation
P/E 0.00
Forward P/E (11.60) (negative: loss-making)
Price / sales 3.27
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.51
Financial health
Current ratio Q 5.89 (at or above 1.5: strong)
Debt / equity Q 0.16 (at or below 0.5: strong)
Interest coverage Q (31.98)
Growth
Revenue growth Q +17.96% (above 0%: growing)
Operating income growth Q −18.04% (below 0%: shrinking)
EPS, this year +0.11%
EPS, next year A +28.98% (at or above 15%: strong)
Revenue, next year A +28.32% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +20.70% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 13.7×; over the ten years it ranged from 1.6× in 2022 to 35.8× in 2022.
P/S against its own 10 years 3.83%
10-year low 10-year high
P/B against its own 10 years 15.07%
10-year low 10-year high
EV/Sales against its own 10 years 6.71%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 257 334 287 218
Receivables 48 83 84 105
Inventory 40 56 71 81
Other — — — —
351 482 450 414
2023 2024 2025 Q'26
Payables 13 10 17 17
ST’ Debt 2 2 — —
Other 6 8 10 9
46 53 66 70

Compound Annual Growth %

10y 5y 3y
Sales — 109.04% 60.14%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 43.11% 22.90%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.39 Actual −0.46

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.32 −0.53 Miss by 0.21
Q1 FY26 −0.55 −0.56 Miss by 0.01
Q2 FY26 −0.46 −0.47 Miss by 0.01
Q3 FY26 −0.39 −0.46 Miss by 0.07
Q4 FY26 −0.25 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.56) (0.47) (0.46) — —
’25 (0.45) (0.35) (0.38) (0.53) (1.72)
’24 (0.51) (0.50) (0.40) (0.35) (1.75)
’23 (0.63) (0.56) (0.51) (0.54) (2.24)
’22 (0.39) (0.43) (0.51) (0.63) (1.96)
’21 (2.65) (2.60) (1.22) (0.42) (3.63)
’20 — — (2.77) — (14.47)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 83 94 98 — —
’25 69 79 83 76 308
’24 45 53 58 68 224
’23 24 33 35 44 136
’22 14 17 20 24 75
’21 7 8 9 10 34
’20 — — 2 — 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (19) (9) — —
’25 (17) (15) (7) (10) (49)
’24 (32) (16) (19) (32) (99)
’23 (36) (28) (19) (25) (108)
’22 (18) (17) (20) (25) (80)
’21 (15) (13) (13) (16) (57)
’20 — — (35) (13) (48)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (41) (22) (10) — —
’25 (19) (18) (10) (12) (58)
’24 (34) (17) (19) (34) (104)
’23 (41) (34) (25) (34) (133)
’22 (18) (17) (21) (26) (83)
’21 (15) (13) (13) (17) (58)
’20 — — (35) (13) (49)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 6 8 34 75 136 224 308 352 +91.9% 395 476 562 +22.2%
Gross margin, % — — — (30.56) (16.26) 46.02 49.44 52.17 61.07 63.70 64.66 +94.3 pt
EBT — — — (42) (53) (60) (87) (106) (91) (95) (110) +14.7%
EBT margin, % — — — (680.42) (687.04) (173.62) (116.18) (77.70) (40.55) (30.96) 0.00 +649.5 pt
Net income — 0 — (42) (53) (60) (87) (106) (91) (96) (115) n/m
Per share, $
Per share, $ Revenue — — — 0.14 2.11 2.09 1.69 2.88 4.31 5.55 6.15 +84.1%
Earnings — — — (0.97) (14.47) (3.63) (1.96) (2.24) (1.75) (1.72) (2.02) +10.0%
Cash flow — — — (1.01) (13.20) (3.48) (1.81) (2.29) (1.90) (0.88) (1.34) (2.3%)
Capex — — — 0.00 (0.06) (0.04) (0.06) (0.53) (0.08) (0.17) (0.15) n/m
Free cash flow — — — (1.01) (13.26) (3.51) (1.87) (2.82) (1.99) (1.05) (1.48) +0.6%
Book value — — — 0.68 16.64 16.21 4.44 5.94 7.72 6.59 5.74 +46.2%
Shares, m — — — 43 4 16 44 47 52 56 57 +4.3%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 0.00 0.00 11.96 23.42 14.38 18.70 5.67 3.27 10.6
P/B — — — 0.00 0.00 1.54 8.91 6.98 10.43 4.78 3.51 4.7
EV/Sales — — — 0.00 0.00 4.68 21.18 12.88 17.45 4.92 2.81 8.7
EV/FCF — — — (1.69) (1.69) (2.79) (19.14) (13.17) (37.80) (25.96) (11.62) (14.6)
Cash, $m
Cash, $m Operating cash flow — — — (44) (48) (57) (80) (108) (99) (49) (77) +1.9%
Capex — — — (8) 0 (1) (3) (25) (4) (9) (8) +3.5%
Free cash flow — — — (44) (49) (58) (83) (133) (104) (58) (85) +4.9%
Balance, $m
Balance, $m Working capital — — — 44 96 310 237 305 429 385 344 +43.8%
Net debt — — — (19) (48) (251) (168) (204) (280) (235) (167) +52.3%
Shareholders’ equity — — — 29 61 267 197 281 402 366 329 +52.4%
Returns, %
Returns, % ROA — — — (135.41) (56.41) (25.85) (26.97) (29.66) (19.48) (18.34) (23.31) +117.1 pt
ROIC — — — 0.00 (225.01) (206.72) (170.70) (88.89) (49.51) (49.56) (45.60) (49.6) pt
ROE — — — 25.69 32.45 (142.17) (37.55) (44.32) (26.77) (24.89) (32.39) (50.6) pt
People
People Employees — — — — 205 234 428 626 756 888 — +34.1%
Revenue/emp, $m — — — 0.00 0.04 0.15 0.18 0.22 0.30 0.35 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

PROCEPT BioRobotics Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ENOV Enovis Corporation $1.7B — (loss-making) 98.6× +1.79% (above 0%: growing) n/m +20.30% (above 0%: growing) 60.83% 0.60% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
TNDM Tandem Diabetes Care, Inc. $1.3B — (loss-making) — (loss-making) +13.82% (above 0%: growing) n/m −231.98% (below 0%: shrinking) 56.55% (0.84%) Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47% Compare
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%)
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60% Compare
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63% Compare
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
Median of peers $1.2B — 38.8× +11.94% — +19.44% 62.43% 1.04%

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Directors and executive officers, together 4.00%
AllianceBernstein L.P. 6.00%
BlackRock, Inc. 5.90%
T. Rowe Price Investment Management, Inc. 5.70%
BNP Paribas Asset Management Holding S.A. 5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

PROCEPT BioRobotics Corporation (PRCT) Latest News

5 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat transcript

4 Nov

Impact 3 · · GlobeNewswire

28 Oct

Impact 3 · · Zacks

25 Oct

Impact 3 · · Simply Wall St.

8 Oct

Impact 4 · · Simply Wall St.

6 Oct

Impact 3 · · Simply Wall St.

11 Aug

Impact 3 · · The Motley Fool transcript

8 Aug

Impact 3 ·

5 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript

4 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

29 Jul

Impact 3 ·

29 Jun

Impact 3 ·

31 May

Impact 3 · · Simply Wall St.

28 May

Impact 4 · · GlobeNewswire

14 May

Impact 4 · · GlobeNewswire

12 May

Impact 4 · · Insider Monkey

4 May

Impact 4 · · Simply Wall St.

1 May

Impact 4 · · Insider Monkey

30 Apr

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 4 · · GuruFocus.com

29 Apr

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

14 Apr

Impact 4 · · The Motley Fool transcript

27 Mar

Impact 4 · · Simply Wall St.

26 Mar

Impact 4 · · Insider Monkey
stockrow.com/PRCT · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com